Drug Repositioning: New Technologies, Business Models & Strategies for Successful Development

Minneapolis, MN -- Big Pharma’s 2012 colossal patent cliff looms. Thirteen blockbuster drugs are set to lose US patent protection; costing industry 70% in lost revenues. Furthermore, despite record R&D investment, biopharmaceutical productivity remains in decline.

Drug repositioning offers the possibility of breathing new life into pharmaceutical R&D. By recycling drug data, repositioning promises to boost production, accelerate and derisk R&D, and enhance product life-cycle management.

The promise of drug repositioning is now driving Big Pharma and Biotech to focus over 50% of its R&D activity into the approach. As the benefits of drug repositioning are being realized by industry; it is vital that stakeholders successfully navigate this challenging yet rewarding R&D paradigm.

Arrowhead Publishers has found that with around 2,000 Phase II and Phase III failed pipeline candidates typically sitting idle in a typical pharma drug library, drug repositioning may resurrect abandoned R&D programs. Success will recoup R&D costs and provide novel, high-value product life-cycle management.

Arrowhead has identified over 50 specialist drug repositioning companies offering unique screening technologies. It is essential that players adopt a multi-disciplined approach by forming collaborations with specialists to gain valid, fast results to unveil new commercial opportunities.

Key questions answered by this report:

Why is there a need for drug repositioning in the biopharmaceutical industry?

What are the major rewards offered by strategic drug repositioning?

What are the major challenges involved in this paradigm; and how can they be overcome?

Who are the key specialist players involved in the market and what business models are they utilizing?

What lessons can investors learn from established repositioned brands?

What products have recently gained FDA approval and what developmental pathway did they take?

How can players optimize strategic drug repositioning to maximize commercial success?

What are the key leading products and pipeline candidates in the market?

How much revenue will the leading products and key pipeline agents reach by 2016?

What financial rewards does the strategy provide?

What recommendations does Arrowhead provide for successful repositioning?

What does the future hold for the drug repositioning market?

For more information about this report, visit www.arrowheadpublishers.com or call 1-312-244-3703 or email us at sales@arrowheadpublishers.com.